Firstly, MYCN amplification is well established in neuroblastoma accounting for 20%-30% of cases (4), but also observed in 25% of alveolar rhabdomyosarcoma cases (4, 41, 42), 5%-10% of medulloblastomas associated with poor prognosis (36, 40). This evidence concerns the gene MYCN and medulloblastoma.